StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the medical equipment provider’s stock.

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

September: Nevro earned FDA approval and began a limited market release of its HFX iQ spinal cord stimulator with HFX AdaptivAI. October: Allied Market Research forecasts the spinal cord stimulator ...

Nevro Corp是一家全球医疗器械公司，专注于提供继续为慢性疼痛治疗持久患者结果设定标准的全面的、改变生活的解决方案。该公司开发并商业化Senza脊髓刺激（SCS）系统。SCS是一个用于治疗慢性疼痛的神经调节平台，除了Senza系列产品之外，还包括Senza Omnia平台 ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

At close: April 1 at 4:00:02 p.m. EDT ...

This Zacks Rank #3 (Hold) company’s shares have fallen 59.2% in the past year compared with the industry’s 7.4% decline. The ...